ArticleMolecular pharmaceutics2026
A Novel Immune-Modulating Nanodrug Enhances Liver-Targeted mRNA Delivery.
Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Liver-specific delivery of mRNAs encoding key regulatory genes via lipid nanoparticles (LNPs) is promising to restore liver homeostasis and resume liver functions in inflammatory liver diseases. However, inflammation downregulates the global mRNA expression in general as a self-defensive mechanism, e.g., to block viral protein expression, which also reduces the efficiency of therapeutic mRNA delivered to hepatocytes. In addition, ionizable LNPs are immunogenic, which exacerbates inflammation. In this project, we applied a novel immune-modulating telodendrimer (TD) nanodrug (ND) to inhibit inflammation and improve specific mRNA delivery. We tested TD ND in both mouse and human immune cells, liver cell lines, and primary human hepatocytes (PHH) to inhibit endotoxin-induced inflammation. TD ND was able to inhibit both endogenous and LPS-induced inflammation in liver cells, which improved cell proliferation in culture and also significantly enhanced the efficiency of mRNA/LNP delivery both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.